Answers are grounded in this paper and cite their sources.
Our results suggest that patients and clinicians may have limited evidence available to inform treatment decisions about high-risk medical devices up to a decade after approval. Policy makers should consider measures to promote timely completion and reporting of postmarket studies. These approaches could include enforcing financial penalties for failure to report results on ClinicalTrials.gov or funding independent comparative effectiveness research using milestone payments linked to study progress and publication.
No takes yet. Share an insight, caveat, or question.
Rathi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: